BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting

Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen (BCMA) has demonstrated incredible results, leading to regulatory approva...

Source: Journal of Hematology and Oncology - July 28, 2023 Category: Hematology Authors: James F. Wu and Binod Dhakal Tags: Correspondence Source Type: research